KERRI MAXCY: Open Payments
NPI 1255711768 · MANHATTAN, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 65 payments from 15 companies in 2025. Trend: 2023 $862 · 2024 $1,249 · 2025 $1,166
Food & beverage: $1,166
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 18 | $262 |
| ABBVIE INC. | 13 | $171 |
| AstraZeneca Pharmaceuticals LP | 5 | $146 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $121 |
| Abbott Laboratories | 2 | $82 |
| GlaxoSmithKline, LLC. | 4 | $70 |
| Novo Nordisk Inc | 3 | $66 |
| Lilly USA, LLC | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Corcept Therapeutics | 3 | $43 |
Products named: CAPLYTA, BREZTRI, PREVNAR 20, VRAYLAR, FREESTYLE LIBRE 3, NURTEC ODT, ELIQUIS, MOUNJARO.
Industry payments across KS — which companies pay providers there.
